Ark Genomic Revolution Ucits ETF AccumUSD
ARKG.L
London Stock Exchange- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 5th Floor, 76 Sir John Rogerson's Quay Dublin Ireland D02 R296
- IPO Date
- Apr 19, 2024
- Website
- europe.ark-funds.com
- Similar Companies
- Business
- ARK Genomic Revolution UCITS ETF AccumUSD (Ticker: ARKG.L) is an exchange-traded fund that provides exposure to a concentrated portfolio of global equities focused on genomic and biotechnological innovation. ARKG.L is managed by ARK Invest's Europe arm and lists on European exchanges, offering Ucits-compliant access to companies pursuing transformative DNA-based research and therapy, gene editing, and related technologies. Main products and services: - Primary product: Ark Genomic Revolution UCITS ETF Accumulated USD; fund structure; UCITS-compliant, accumulating share class; daily priced ETF; secondary market liquidity through major European exchanges - Investment objective and exposure: seeks long-term growth by tracking a diversified basket of global equities associated with genomic and biotechnological innovation, including gene therapy, genetic sequencing, CRISPR and related technologies, and related healthcare services - Index methodology and governance: rules-based selection of genomics names; annual rebalancing; transparent tracking of the index; fiduciary oversight by fund sponsor and sub-advisers - Fund administration and share classes: accumulating share class; custody and fund accounting; dividend handling (reinvested); secondary market trading in EUR and USD denominations where available Latest major company changes: - Strategic expansions in Europe to broaden access to genomics-focused ETF products and compliance with UCITS framework - Partnerships or alliances with European distributors and platform providers to enhance reach and liquidity - Product enhancements or launches related to name, branding, or service offering within the ARK Funds umbrella - Operational changes including regulatory approvals, fund launches, or reorganizations within the last 1-2 years Additional context: - Industry and segments: exchange-traded funds; thematic investing; biotechnology and life science equities - Target markets and customers: individual and institutional investors seeking thematic exposure to genomics and biotech innovation - Geographic operations: Europe (UCITS platform), with underlying global holdings - Founding year and headquarters: ARK Invest entities established earlier in the 2010s; specific UCITS platform headquartered in Europe under ARK’s European arm - Subsidiaries/parent relationships: part of the ARK Funds family; linked to ARK Invest ecosystem and governance framework